Computational methods for identifying cancer treatments, including molecular screening and digital twins.Computational methods for cancer drug discovery use algorithms and simulations to identify promising drug candidates, predict their effectiveness, and understand how tumors might respond to treatment. This includes virtual screening of molecular libraries, modeling drug-target interactions, and creating 'digital twins' of tumors to simulate therapy outcomes. The goal is to shorten the years-long pipeline from molecule to approved drug and to personalize treatments for individual patients.
The field began in the 1980s with structure-based drug design, but the integration of big data and AI accelerated it in the 2010s. The concept of digital twins in medicine gained prominence in the late 2010s, driven by advances in imaging and genomics.
One approach involves docking simulations, where a computer predicts how a small molecule fits into a protein's active site. Machine learning models can also be trained on large datasets of known drug responses to predict which compounds are likely to work against specific cancer types. Digital twins use patient-specific data—such as genomic profiles and imaging—to build a computational model of the tumor, which can then be 'treated' virtually to test different drug combinations before applying them to the patient.
Used by pharmaceutical companies to screen millions of compounds in silico, and in clinical settings to predict which patients will respond to immunotherapy or chemotherapy based on their tumor's molecular profile.
Digital twins of tumors can simulate the evolution of drug resistance, allowing doctors to preemptively switch therapies before the cancer becomes untreatable.

















